PATENT CLAIM ANALYSIS

Application Number: 15926015
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "279000"]

Abstract:
This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Claim (Index 2):
The method of  claim 1 , wherein said hematologic cancer is selected from the group consisting of: acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, and Hodgkin's disease.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 90.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15379649', '14400896', '13696436', '14458305', '13990505']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.79788812973734
- 35 USC 102 Novelty (BERT): 0.5334681445593624
- Combined Prediction Score: 0.7714461312195423
- Mean Citation Score: 313.60831
- Max Citation Score: 315.5898
- Similarity Product: 160.05540957713131

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test